A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Triamcinolone
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 07 Dec 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
- 07 Dec 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Feb 2018.
- 07 Dec 2017 Status changed from recruiting to active, no longer recruiting.